Harry W. Alcorn Jr. is VP at DiaMedica Therapeutics Inc. (DMAC). They have made 5 open-market trades across 1 company since 2018, most recently 2021-09-15.
CIK 0001186761
5 open-market purchases totalling $145K since 2018, never a sale. Across 5 scored buys the stock is up 6.2% at ninety days, and 1.9 points ahead of the S&P over the same stretch.
5 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| DMAC | 43,582 | $332K |
Shares reported on the most recent Form 4, priced at the 2021-09-15 close.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 40% | 60% | 60% |
| Avg Move | -6.2% | -0.5% | +6.2% |
| Alpha | -4.1% | -1.2% | +1.9% |
| Scored | 5 | 5 | 5 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| DMAC | BUY | 2021-09-15 | 2021-09-15 | $3.80 | $57K | +4.0% | +2.5% | -6.0% |
| DMAC | BUY | 2021-08-16 | 2021-08-16 | $3.09 | $64K | +15.3% | +13.8% | +18.5% |
| DMAC | BUY | 2019-08-16 | 2019-08-16 | $2.67 | $19K | -4.2% | +9.7% | +27.0% |
| DMAC | BUY | 2019-03-27 | 2019-03-29 | $4.46 | $669 | -19.6% | -26.0% | +2.6% |
| DMAC | BUY | 2018-12-11 | 2018-12-11 | $4.00 | $4K | -26.7% | -2.7% | -11.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.